stock

Incyte Corp. (INCY)

Share

Stay up to date

incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.

Financial Statements

Key Info

  • Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
  • Sector: Professional, Scientific, and Technical Services
  • CEO Name: Herve Hoppenot

Key Statistics

  • Stock Price: $58.76
  • Dividend Yield: 0%
  • Market Capitalization: $13,551,885,622
  • Shares Outstanding: 224,109,238
  • Number of Employees: 2,600
  • Trailing 12-Month EPS: $1.88
  • Trailing 12-Month DPS: $0
  • Payout Ratio: 0.0%

Important Dates

  • Next Earnings Date: 2024-02-13
  • Next Ex-Dividend Date:

Price Trends

  • Current Stock Price: $58.76
  • 52-week high: $86.05
  • 52-week low: $50.27
  • 200-day moving average: $60.06
  • 50-day moving average: $62.67

Performance

  • 1-Month Price Return: -3.7%
  • 3-Month Price Return: 15.1%
  • 6-Month Price Return: -4.2%
  • 1-Year Price Return: -29.4%
  • 2-Year Price Return: -18.5%
  • 5-Year Price Return: -23.7%

Visit the Passiv Stock Directory

Data provided by IEX Cloud

For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast